Delisting risk
AIM ImmunoTech
Develops Ampligen as an immunotherapy adjunct for metastatic pancreatic cancer.
$0.2289
Pre-market−0.00 (−0.91%)
At close$0.2310(−10.60%)
Something off on this page? Send us feedback.
Next report
Nov 16, 2026
in 76 days
EPS estimate
−$0.12
Revenue estimate
$25.7K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$10.00−$5.00−$3.68−$1.57−$0.44−$0.69−$0.43Pending
Estimate−$9.00−$8.00−$8.00−$0.97−$0.94−$1.08−$0.17−$0.12
Surprise−11.1%+37.5%+54.0%−61.0%+53.2%+36.1%−152.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$45.0K$16.0K$25.0K$26.0K$21.0K$11.0K$26.0KPending
Estimate$100.0K—$100.0K—$100.0K$11.0K$100.0K$25.7K
Surprise−55.0%—−75.0%—−79.0%0.0%−74.0%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.17 | −$0.43 | −152.9% |
| May 2026 | −$1.08 | −$0.69 | +36.1% |
| Mar 2026 | −$0.94 | −$0.44 | +53.2% |
| Nov 2025 | −$0.97 | −$1.57 | −61.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Apr 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Apr 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | −$0.12 | — | — | $25.7K | — | — | — |
| Aug 7, 2026 | −$0.17 | −$0.43 | −152.9% | $100.0K | $26.0K | −74.0% | +5.4% |
| May 15, 2026 | −$1.08 | −$0.69 | +36.1% | $11.0K | $11.0K | 0.0% | +61.3% |
| Mar 27, 2026 | −$0.94 | −$0.44 | +53.2% | $100.0K | $21.0K | −79.0% | −21.3% |
| Nov 17, 2025 | −$0.97 | −$1.57 | −61.0% | — | $26.0K | — | −7.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 16, 2024 | |||||||
| Mar 29, 2024 | |||||||
| Nov 14, 2023 | |||||||
| Aug 15, 2023 | |||||||
| May 12, 2023 | |||||||
| Apr 3, 2023 | |||||||
| Nov 15, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Nov 16, 2021 | |||||||
| Aug 17, 2021 | |||||||
| May 18, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Nov 13, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 13, 2020 | |||||||
| Mar 30, 2020 | |||||||
| Nov 14, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 16, 2019 | |||||||
| Apr 1, 2019 | |||||||
| Nov 14, 2018 | |||||||
| Aug 14, 2018 | |||||||
| May 15, 2018 | |||||||
| Mar 30, 2018 | |||||||
| Nov 14, 2017 | |||||||
| Aug 15, 2017 | |||||||
| May 15, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Nov 14, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 16, 2016 | |||||||
| Mar 29, 2016 | |||||||
| Nov 13, 2015 | |||||||
| Aug 12, 2015 | |||||||